CardieX (ASX:CDX) Common Stock : A$76.66 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is CardieX Common Stock?

CardieX's quarterly common stock increased from Dec. 2022 (A$73.01 Mil) to Jun. 2023 (A$76.62 Mil) and increased from Jun. 2023 (A$76.62 Mil) to Dec. 2023 (A$76.66 Mil).

CardieX's annual common stock increased from Jun. 2021 (A$59.29 Mil) to Jun. 2022 (A$67.55 Mil) and increased from Jun. 2022 (A$67.55 Mil) to Jun. 2023 (A$76.62 Mil).

CardieX Common Stock Historical Data

The historical data trend for CardieX's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardieX Common Stock Chart

CardieX Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

51.50

53.13

59.29

67.55

76.62

CardieX Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															67.50	67.55	73.01	76.62	76.66

CardieX Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

CardieX (ASX:CDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CardieX Ltd (ASX:CDX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

55 Lime Street, Suite 301, Level 3, Sydney, NSW, AUS, 2000

Website

https://www.cardiex.com

CardieX Ltd is a global health technology company, developing solutions for health disorders. The AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its patented SphygmoCor technology. It also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. It reports in a single segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company has three reportable segments by geographic area namely the Americas includes, global pharmaceutical trials business, Europe includes, the Middle East and Africa and the Asia Pacific includes, Asia and Australia/New Zealand.

CardieX (ASX:CDX) Headlines

No Headlines